Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 4
2013 2
2014 3
2015 2
2016 1
2017 5
2018 3
2019 2
2020 4
2021 5
2022 8
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean sandra ortizcuaran (3 results)?
Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.
Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, Fekiri D, Robert M, Baffert KA, Hervé G, Quilhot P, Attignon V, Girod A, Chaine A, Benassarou M, Zrounba P, Caux C, Ghiringhelli F, Lantuejoul S, Crozes C, Brochériou I, Pérol M, Fayette J, Bertolus C, Saintigny P. Foy JP, et al. Among authors: ortiz cuaran s. Eur J Cancer. 2022 Oct;174:287-298. doi: 10.1016/j.ejca.2022.06.034. Epub 2022 Aug 26. Eur J Cancer. 2022. PMID: 36038492
Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer.
Ortiz-Cuaran S, Swalduz A, Foy JP, Marteau S, Morel AP, Fauvet F, De Souza G, Michon L, Boussageon M, Gadot N, Godefroy M, Léon S, Tortereau A, Mourksi NE, Leonce C, Albaret MA, Dongre A, Vanbervliet B, Robert M, Tonon L, Pommier RM, Hofman V, Attignon V, Boyault S, Audoynaud C, Auclair J, Bouquet F, Wang Q, Ménétrier-Caux C, Pérol M, Caux C, Hofman P, Lantuejoul S, Puisieux A, Saintigny P. Ortiz-Cuaran S, et al. Eur J Cancer. 2022 Jul;169:106-122. doi: 10.1016/j.ejca.2022.03.038. Epub 2022 May 9. Eur J Cancer. 2022. PMID: 35550950
Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer.
Müller N, Lorenz C, Ostendorp J, Heisel FS, Friese UP, Cartolano M, Plenker D, Tumbrink H, Heimsoeth A, Baedeker P, Weiss J, Ortiz-Cuaran S, Büttner R, Peifer M, Thomas RK, Sos ML, Berg J, Brägelmann J. Müller N, et al. Among authors: ortiz cuaran s. Cancer Res. 2023 Aug 1;83(15):2471-2479. doi: 10.1158/0008-5472.CAN-22-2605. Cancer Res. 2023. PMID: 37289018
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
Tabbò F, Pisano C, Mazieres J, Mezquita L, Nadal E, Planchard D, Pradines A, Santamaria D, Swalduz A, Ambrogio C, Novello S, Ortiz-Cuaran S; BOLERO Consortium. Tabbò F, et al. Among authors: ortiz cuaran s. Cancer Treat Rev. 2022 Feb;103:102335. doi: 10.1016/j.ctrv.2021.102335. Epub 2021 Dec 31. Cancer Treat Rev. 2022. PMID: 35033867 Review.
39 results